We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.16 USD
-13.45 (-8.07%)
Updated May 28, 2024 03:53 PM ET
After-Market: $153.20 +0.04 (0.03%) 4:10 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
View All Zacks #1 Ranked Stocks
Zacks News
Market Gains on Powell's Speech and Moderna's Vaccine
by Zacks Equity Research
Market Gains on Powell's Speech and Moderna's Vaccine.
Moderna (MRNA) COVID-19 Vaccine Looks Promising
by Mark Vickery
This news comes sooner and more positive than analysts had been expecting, and shares are up 35% in early trading this Monday.
Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Traders Focus on Powell's Comments
by Jeremy Mullin
Futures are flying high before the bell.
Stocks Take a Breather, but Good Weekend News Promises a Boost
by David Borun
Positive comments from the Fed Chairman and promising vaccine trial results provide a chance for a meaningful rally.
Healthcare Tech & Robotics ETFs in Focus amid COVID-19 Crisis
by Neena Mishra
The pandemic will forever transform our lives; here are some areas that may benefit.
The Zacks Analyst Blog Highlights: NVIDIA, Moderna, Clorox, Campbell Soup and General Mills
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Moderna, Clorox, Campbell Soup and General Mills
Rebalance Your Portfolio to Counter Dilemma Over Recovery
by Nalak Das
At this stage, a combination of aggressive and defensive stocks after filtering with proper selection criteria will be prudent for one's portfolio.
Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine
by Zacks Equity Research
Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.
Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners
by Zacks.com
Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.
The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox
Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain
by Sweta Jaiswal, FRM
Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.
6 Leveraged ETFs Up At Least 25% Last Week
by Sanghamitra Saha
Oil, tech and biotech caused a rally in the leveraged ETF space last week.
An Outstanding Week for Market Amid Record Job Losses: 5 Picks
by Nalak Das
Market's worst is behind us as negative estimates are already factored in valuations.
6 ETF Areas Beating S&P 500 in 2020
by Sanghamitra Saha
The S&P 500 is down 10.8% this year, after a massive recovery in April. But these ETF areas have beaten the S&P 500 this year.
Moderna (MRNA) Q1 Loss Narrows, Revenues Miss Estimates
by Zacks Equity Research
Moderna (MRNA) reports narrower-than-expected first-quarter loss. The company plans to initiate phase II study on coronavirus vaccine soon.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 5.41% and -53.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Biotech ETFs Poised to Benefit From Coronavirus
by Neena Mishra
Rising investor interest in coronavirus related stocks will benefit these ETFs
5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up
by Zacks Equity Research
As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.
Coronavirus Vaccine Efforts to Aid Moderna (MRNA) Q1 Earnings?
by Zacks Equity Research
Moderna (MRNA) is progressing with coronavirus vaccine development. While grants for development are expected to have aided revenues, increased clinical activity is expected to have increased expenses.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Moderna, Twilio and Wayfair
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Twilio and Wayfair
3 Sector ETFs Gaining Momentum in May
by Sanghamitra Saha
After a wobbly start, Wall Street steadied in May. These sector ETFs contributed the most in Wall Street recovery on Monday.
Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Progress of its pipeline candidates, especially coronavirus vaccine, is likely to have increased Moderna's (MRNA) operating expenses in the first quarter.